Financially, Rhythm has $319.1 million in cash, but may need to raise more funds within the next 12 months. See why I rate ...
The drugmaker was supposed to hear back from the FDA on mavacamten at the end of January, but the regulator delayed its deadline to 28 April to allow more time to look at BMS' risk evaluation and ...
The bioavailability of pantoprazole when administered as a suspension in sodium bicarbonate solution and as the oral tablet was studied. In an open-label, randomized, two-period crossover study ...